Veru Inc Asset Resilience Ratio
Veru Inc asset resilience ratio. Veru Inc (VERU) has an Asset Resilience Ratio of 5.31% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Veru Inc (VERU) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Veru Inc (2003–2025)
Asset resilience ratio of Veru Inc from 2003 to 2025. This chart shows how Veru Inc's Asset Resilience Ratio has changed over time. Read debt load of Veru Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Veru Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VERU total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.53 Million | 5.31% |
| Total Liquid Assets | $2.53 Million | 5.31% |
Asset Resilience Insights
- Limited Liquidity: Veru Inc maintains only 5.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Veru Inc Industry Peers by Asset Resilience Ratio
Compare Veru Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Veru Inc Asset Resilience Ratio by Year (2003–2025)
Veru Inc asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for Veru Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 8.46% | $2.53 Million | $29.84 Million | +7.24pp |
| 2024-09-30 | 1.23% | $742.29K | $60.42 Million | -- |
| 2018-09-30 | 0.00% | $0.00 | $48.45 Million | -- |
| 2017-09-30 | 0.00% | $0.00 | $55.31 Million | -- |
| 2016-09-30 | 0.00% | $0.00 | $38.62 Million | -- |
| 2015-09-30 | 0.00% | $0.00 | $37.47 Million | -- |
| 2014-09-30 | 0.00% | $0.00 | $31.67 Million | -- |
| 2013-09-30 | 0.00% | $0.00 | $35.17 Million | -- |
| 2012-09-30 | 0.02% | $5.00K | $30.45 Million | -0.34pp |
| 2011-09-30 | 0.35% | $69.00K | $19.44 Million | +0.33pp |
| 2010-09-30 | 0.03% | $5.00K | $18.37 Million | -0.54pp |
| 2009-09-30 | 0.57% | $105.00K | $18.54 Million | -0.97pp |
| 2008-09-30 | 1.53% | $212.00K | $13.83 Million | +0.76pp |
| 2007-09-30 | 0.77% | $86.00K | $11.19 Million | -2.43pp |
| 2006-09-30 | 3.20% | $238.00K | $7.45 Million | +0.81pp |
| 2003-09-30 | 2.38% | $120.00K | $5.04 Million | -- |
About Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosa… Read more